LogiCare3PL Selected as Distribution Partner by Harrow
Rhea-AI Summary
Harrow (Nasdaq: HROW) has selected LogiCare3PL as its U.S. distribution partner for Harrow's ophthalmic disease management solutions. Effective Feb 1, 2026, LogiCare3PL will provide both non-title logistics and 3PL title distribution across the U.S., meeting Harrow's rapid onboarding needs.
LogiCare3PL completed Harrow's onboarding in four weeks, supporting faster, cost-effective market access while maintaining high-touch customer engagement and continuity of supply.
Positive
- Agreement effective Feb 1, 2026
- Onboarded Harrow in 4 weeks, meeting implementation timeline
- Provides both non-title and 3PL title distribution services
- Supports U.S. nationwide market access for Harrow products
Negative
- None.
News Market Reaction – HROW
On the day this news was published, HROW gained 2.16%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
HROW’s positive move of 3.26% occurs alongside mixed peer action: AMPH up 5.9%, PAHC up 3.29%, while BGM is down 4.9% and BCRX is down 0.98%, indicating stock-specific rather than broad sector momentum.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 24 | Debt financing | Neutral | +3.3% | Priced $50M add-on of 8.625% 2030 notes for general corporate purposes. |
| Mar 24 | Debt financing | Neutral | +3.5% | Announced intent for $50M additional 2030 notes to support growth initiatives. |
| Mar 18 | Scientific meeting | Positive | -2.1% | Three ASCRS 2026 abstracts accepted featuring VEVYE and ILEVRO product data. |
| Mar 04 | Conference appearance | Positive | +1.6% | Planned presentation at Leerink Partners 2026 Global Healthcare Conference. |
| Mar 03 | Clinical trial | Positive | -28.0% | FDA-cleared IND for Phase 3 TRIESENCE trial in post-cataract inflammation and pain. |
Recent history shows occasional sharp negative reactions to positive clinical or scientific updates, while financing and conference news have coincided with modest gains.
Over the last six weeks, Harrow reported several notable events. On March 3–4, 2026, it announced an IND-supported Phase 3 trial for TRIESENCE and a Leerink conference appearance, with the trial news seeing a -27.96% move despite its growth focus. Two $50.0 million senior note offerings on March 24, 2026 each coincided with gains above 3%. Scientific visibility increased with three ASCRS 2026 abstracts on March 18, 2026, which saw a mild decline. Today’s logistics partnership fits into a broader commercialization and expansion trajectory.
Market Pulse Summary
This announcement details Harrow’s selection of LogiCare3PL as a U.S. distribution partner effective February 1, 2026, covering non-title logistics and full 3PL title services. It fits alongside recent financing and clinical initiatives, emphasizing commercialization readiness for an ophthalmic portfolio. Investors may focus on how this partnership affects product availability, onboarding speed—already demonstrated within four weeks—and support for future product launches, while tracking subsequent disclosures on sales trends and operational performance.
Key Terms
ophthalmic medical
3pl technical
AI-generated analysis. Not financial advice.
LogiCare3PL was selected for its high-touch service model, proven ability to execute quickly and efficiently, and commitment to building a long-term partnership. These capabilities were essential in supporting Harrow's need for rapid onboarding and market readiness.
This partnership enables faster, more cost-effective market access for Harrow's products, while maintaining a high level of engagement and support from the LogiCare3PL team. LogiCare3PL successfully onboarded Harrow within just four weeks, meeting Harrow's implementation timeline and ensuring business continuity.
Kevin Kissling, VP/GM 3PL Services for LogiCare3PL, commented: "We are proud to partner with Harrow and support their broad portfolio of ophthalmic disease management solutions. At LogiCare3PL, we are committed to delivering on every promise we make and developing solutions that meet each manufacturer's specific needs. Harrow and LogiCare3PL's shared focus on flexibility, customer-centricity, and rapid execution makes this collaboration especially meaningful."
The agreement, effective February 1, 2026, covers LogiCare3PL's full suite of 3PL services, including non-title logistics support and title distribution for Harrow's products. Both organizations anticipate continued collaboration as Harrow expands its product offerings.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in
About LogiCare3PL
LogiCare3PL, a BioCare company, is a trusted pharmaceutical third‑party logistics partner serving emerging and mid‑sized biopharmaceutical manufacturers. Specializing in specialty, rare, and ultra‑rare disease therapies, LogiCare3PL delivers tailored, end‑to‑end solutions including time‑ and temperature‑sensitive logistics, centralized warehousing, financial services, regulatory compliance and licensing support, advanced data analytics, and comprehensive manufacturer and customer care. Through an integrated, compliant, and reliable approach, LogiCare3PL ensures products move securely from manufacturer to market. With unmatched reliability and expertise, LogiCare3PL sets the standard for precision and trust in pharmaceutical logistics.
Media Contact:
BioCare, Inc.
Barbara Pantazopoulos
VP Marketing & Communications
barbara.pantazopoulos@biocaresd.com
biocare-us.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/logicare3pl-selected-as-distribution-partner-by-harrow-302741856.html
SOURCE LogiCare3PL